(1) Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …

(1) Objectives: To assess the impact of optimal joint pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam monotherapy …

Purpose Standard dosing and intermittent bolus application (IB) are important risk factors for
pharmacokinetic (PK) target non-attainment during empirical treatment with β-lactams in …

Pharmacokinetic changes are often seen in patients with severe infections. Administration
by continuous infusion has been suggested to optimize antibiotic exposure and …

Objectives We utilized the database of the Defining Antibiotic Levels in Intensive care unit
patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and …

Importance of the field: Piperacillin-tazobactam is a frequently prescribed intravenous
antibiotic for moderate to severe infections used in hospital settings because of its broad …

Introduction To enhance the probability of pharmacodynamic target attainment, piperacillin–
tazobactam can be administered as either a continuous or extended-infusion dosage …

Studies evaluating the outcomes of an extended-infusion (EI) piperacillin-tazobactam dosing
strategy in specific cohorts of critically ill patients are lacking. A retrospective, pre …

The clinical efficacy of continuous infusion of piperacillin/tazobactam in critically ill patients
with microbiologically documented infections is currently unknown. We conducted a …

Objective The study was to establish a population pharmacokinetic (PPK) model of
piperacillin (PIP) and tazobactam (TAZ) that explain pharmacokinetic variability and to …